Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.5
Substance Class Chemical
Record UNII
YO460OQ37K
Record Status Validated (UNII)
Record Version
Show Definitional References Hide Definitional References
Download

Details

Stereochemistry ACHIRAL
Molecular Formula C22H24BrFN4O2
Molecular Weight 475.354
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
Created by admin on Thu Mar 26 02:34:51 EDT 2020
Edited by admin on Thu Mar 26 02:34:51 EDT 2020
Structure of VANDETANIB

Systematic Names:

  • None recorded
  • {{name}}

SMILES

COC1=CC2=C(C=C1OCC3CCN(C)CC3)N=CN=C2NC4=CC=C(Br)C=C4F

InChI

UHTHHESEBZOYNR-UHFFFAOYSA-N
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
Name Type Language Details References
VANDETANIB
Domain Jurisdiction Naming Organization
drug  
INN   USAN  
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
Official Name
English  
GNF-PF-2188
Code
English  
VANDETANIB [VANDF]
Common Name
English  
VANDETANIB [MART.]
Common Name
English  
CAPRELSA
Brand Name
English  
VANDETANIB [INN]
Common Name
English  
ZD6474
Code
English  
VANDETANIB [WHO-DD]
Common Name
English  
N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE
Systematic Name
English  
VANDETANIB [USAN]
Common Name
English  
VANDETANIB [JAN]
Common Name
English  
VANDETANIB [MI]
Common Name
English  
VANDETANIB [ORANGE BOOK]
Common Name
English  
4-QUINAZOLINAMINE, N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYL-4- PIPERIDINYL)METHOXY)-
Systematic Name
English  
ZD-64
Code
English  
ZACTIMA
Brand Name
English  
ZD-6474
Code
English  
Classification Tree Code System Code References
EMA ASSESSMENT REPORTS CAPRELSA (AUTHORIZED: THYROID NEOPLASMS)
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
LIVERTOX 1021
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
NDF-RT N0000175605
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
NCI_THESAURUS C1742
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
NCI_THESAURUS C2167
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
EU-Orphan Drug EU/3/05/344
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
WHO-ATC L01XE12
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
NCI_THESAURUS C93259
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
FDA ORPHAN DRUG 211005
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
WHO-VATC QL01XE12
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
Code System Code Type Description References
IUPHAR
5717
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
NDF-RT
N0000185503
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY P-Glycoprotein Inhibitors [MoA]
EVMPD
SUB29174
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
ChEMBL
CHEMBL24828
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
NDF-RT
N0000187061
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY Organic Cation Transporter 2 Inhibitors [MoA]
NCI_THESAURUS
C2737
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
CAS
443913-73-3
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
HSDB
443913-73-3
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
INN
8365
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
EPA CompTox
443913-73-3
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
MERCK INDEX
M11387
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY Merck Index
DRUG BANK
DB05294
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
PUBCHEM
3081361
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
LactMed
443913-73-3
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
RXCUI
1098413
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY RxNorm
MESH
C452423
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
PRIMARY
Related Record Type Details References
TRANSPORTER -> INHIBITOR
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
TARGET -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 09:28:28 EDT 2020 , Edited by admin on Thu Mar 26 09:28:28 EDT 2020
METABOLIC ENZYME -> SUBSTRATE
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
METABOLIC ENZYME -> SUBSTRATE
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
TARGET -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 05:52:31 EDT 2020 , Edited by admin on Thu Mar 26 05:52:31 EDT 2020
TARGET -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 09:28:39 EDT 2020 , Edited by admin on Thu Mar 26 09:28:39 EDT 2020
TARGET -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:53 EDT 2020 , Edited by admin on Thu Mar 26 02:34:53 EDT 2020
EXCRETED UNCHANGED
Mediator Substance Details
none
Within a 21-day collection period after a single dose of 14C-vandetanib, approximately 69% was recovered with 44% in feces and 25% in urine.
FECAL
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
EXCRETED UNCHANGED
Mediator Substance Details
none
Within a 21-day collection period after a single dose of 14C-vandetanib, approximately 69% was recovered with 44% in feces and 25% in urine.
URINE
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
BINDER->LIGAND
Mediator Substance Details
none
BINDING
Created by admin on Thu Mar 26 02:34:54 EDT 2020 , Edited by admin on Thu Mar 26 02:34:54 EDT 2020
METABOLIC ENZYME -> SUBSTRATE
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:56 EDT 2020 , Edited by admin on Thu Mar 26 02:34:56 EDT 2020
TARGET -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
TRANSPORTER -> INHIBITOR
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:59 EDT 2020 , Edited by admin on Thu Mar 26 02:34:59 EDT 2020
TRANSPORTER -> SUBSTRATE
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:35:00 EDT 2020 , Edited by admin on Thu Mar 26 02:35:00 EDT 2020
Related Record Type Details References
METABOLITE INACTIVE -> PARENT
none
Mediator Substance Details
none
FECAL; PLASMA; URINE
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
METABOLITE ACTIVE -> PARENT
none
Mediator Substance Details
none
MAJOR
FECAL; PLASMA; URINE
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
Related Record Type Details References
ACTIVE MOIETY
none
none
Mediator Substance Details
none
Created by admin on Thu Mar 26 02:34:52 EDT 2020 , Edited by admin on Thu Mar 26 02:34:52 EDT 2020
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Note References
[Validation]WARNING:Code 'N0000175605'[NDF-RT] collides (possible duplicate) with existing code & codeSystem for substance:
[I42748ELQW]ACALABRUTINIB
[Validation]WARNING:Code 'N0000185503'[NDF-RT] collides (possible duplicate) with existing code & codeSystem for substance:
[5018V4AEZ0]BOSUTINIB
[Validation]WARNING:Code 'N0000187061'[NDF-RT] collides (possible duplicate) with existing code & codeSystem for substance:
[AN164J8Y0X]TRIMETHOPRIM
Created Thu Mar 26 02:34:51 EDT 2020
Created By admin
Last Edited Thu Mar 26 02:34:51 EDT 2020
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File
1 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails SRS NOMEN
2 VANDETANIB [DASH] SRS_LOCATOR
3 Generated from relationship on:'MULTIDRUG RESISTANCE PROTEIN 1' SYSTEM
4 SRS import [YO460OQ37K] SRS NOMEN Fri Apr 28 14:45:04 EDT 2017
5 HTTP://WWW.TANDFONLINE.COM/DOI/PDF/10.1517/17425255.2015.1006626 WEBSITE NOMEN
6 USP DICTIONARY 2009 SRS NOMEN
7 WEBSITE WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
8 Generated from relationship on:'EPHRIN TYPE-A RECEPTOR 8' SYSTEM
9 HTTP://WWW.TANDFONLINE.COM/DOI/PDF/10.1517/17425255.2015.1006626 WEBSITE NOMEN
10 MERCK INDEX SRS NOMEN
11 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1823 WEBSITE NOMEN
12 FDA_SRS SRS NOMEN
13 Generated from relationship on:'OCT-2' SYSTEM
14 VANDETANIB [JAN] SRS_LOCATOR
15 USAN COUN 2005 USANCOUN NOMEN PUBLIC_DOMAIN_RELEASE
16 WEBSITE WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
17 https://www.clinicalkey.com/pharmacology/monograph/3722?sec=monphar CLINICAL PHARMACOLOGY
18 VANDETANIB [WHO-DD] SRS_LOCATOR
19 Trends in Pharmacological Sciences, November 2014, Vol. 35, No. 11 604-620 WEBSITE NOMEN
20 Generated from relationship on:'EPHRIN TYPE-B RECEPTOR 2' SYSTEM
21 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1828 WEBSITE NOMEN
22 KEGG 2011 SRS NOMEN
23 KATHAWALA, R.J., ET AL., THE MODULATION OF ABC TRANSPORTER-MEDIATED MULTIDRUG RESISTANCE IN CANCER: A REVIEW OF THE PAST DECADE. DRUG RESIST. UPDAT. (2014), HTTP://DX.DOI.ORG/10.1016/J.DRUP.2014.11.002 CAS NOMEN
24 WHO-DD SRS NOMEN
25 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
26 SYSTEM
27 VANDETANIB [VANDF] SRS_LOCATOR
28 CHEMBL SRS NOMEN
29 USP Dictionary 2007 SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
30 GSRS System-generated Validation messages VALIDATION_MESSAGE Thu Mar 26 02:34:50 EDT 2020
31 VANDETANIB [MART.] SRS_LOCATOR
32 VANDETANIB [ORANGE BOOK] SRS_LOCATOR
33 VANDETANIB [MI] SRS_LOCATOR
34 INN 2010 SRS NOMEN
35 SRS CODE IMPORT SRS NOMEN Fri Apr 28 14:45:04 EDT 2017
36 Generated from relationship on:'EPHRIN TYPE-A RECEPTOR 3' SYSTEM
37 MARTINDALE 2011 SRS NOMEN
38 VANDETANIB [INN] SRS_LOCATOR
39 VANDETANIB [USAN] SRS_LOCATOR
40 WEBSITE WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
41 http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1831 WEBSITE NOMEN
42 GSRS System-generated Validation messages VALIDATION_MESSAGE Thu Mar 26 02:34:50 EDT 2020
43 WIKIPEDIA SRS NOMEN
44 USP DICTIONARY 2011 SRS NOMEN
45 NDF-RT SRS NOMEN
46 Generated from relationship on:'OATP-8' SYSTEM
47 STN STN (SCIFINDER)
48 OB SRS NOMEN

Version

Version Comments

Editor

Change Date

24
admin
Thu Mar 26 05:28:39 EDT 2020
23
admin
Thu Mar 26 05:28:28 EDT 2020
22
admin
Thu Mar 26 01:52:31 EDT 2020

Molecular Formula C22H24BrFN4O2
Molecular Weight 475.354
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE